Comparing the associations between host and tumor factors with survival outcomes with anti‐PD‐1 immunotherapy in metastatic melanoma

BACKGROUND: Anti‐programmed death‐1 (PD‐1) immunotherapy has drastically improved survival for metastatic melanoma; however, 50% of patients have progression within 6 months despite treatment. In this study, we investigated host, and tumor factors for metastatic melanoma patients treated with anti‐P...

Descripción completa

Detalles Bibliográficos
Autores principales: Koczka, Kim, Rigo, Rodrigo, Batuyong, Eugene, Cook, Sara, Asad, Mohammad, Vallerand, Isabelle, Suo, Aleksi, Wang, Edwin, Cheng, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939151/
https://www.ncbi.nlm.nih.gov/pubmed/35924450
http://dx.doi.org/10.1002/cam4.5070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939151/
https://www.ncbi.nlm.nih.gov/pubmed/35924450
http://dx.doi.org/10.1002/cam4.5070

Ejemplares similares